A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098

<h4>Background</h4> <p>GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor. Preclinical studies demonstrate growth inhibition in glioblastoma cell lines. However, rodent studies indicate limited blood–brain barrier (BBB) penetration. In this expansion cohort within a...

Full description

Bibliographic Details
Main Authors: Brown, N, Williams, M, Arkenau, H, Fleming, R, Tolson, J, Yan, L, Zhang, J, Swartz, L, Singh, R, Auger, K, Lenox, L, Cox, D, Lewis, Y, Plisson, C, Searle, G, Saleem, A, Blagden, S, Mulholland, P
Format: Journal article
Language:English
Published: Oxford University Press 2018
Subjects:
focal adhesions
kinetics
neoplasms
pharmacokinetics
cerebral edema
fatigue
positron-emission tomography
brain
toxic effect
phosphotransferases
glioblastoma
safety
kinase inhibitors

Similar Items